MedTrace Logo

Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

NCT00325767 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2006-05-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether lung mucociliary clearance (MCC) can be significantly enhanced in healthy subjects by one week of inhalation of nebulized levalbuterol aerosol, as compared to racemic albuterol or placebo. Subjects will inhale one week of levalbuterol, one week of racemic albuterol, and one week of placebo, in a randomized order.

Conditions

  • Mucociliary Clearance

Interventions

DRUG

nebulized albuterol (2.5 mg/3ml/dose)

DRUG

nebulized levalbuterol (1.25 mg/3ml/dose)

DRUG

nebulized placebo (3ml/dose)

Sponsors & Collaborators

Principal Investigators

  • Beth L Laube, Ph.D. · Johns Hopkins University

  • Jeffrey C Cleary, M.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-05-31
Completion
2005-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00325767 on ClinicalTrials.gov